HYBIO(SZ:300199)2022-12-06 11:01Group 1: Company Overview and Performance - Shenzhen Hanyu Pharmaceutical Co., Ltd. completed the acquisition of Chengji Pharmaceutical in February 2015, enhancing its management and operational capabilities [2] - The company successfully upgraded Chengji Pharmaceutical's production capacity in Q4 2015, laying a solid foundation for achieving annual operational goals [2] - Hanyu aims to leverage Chengji's production scale and cost advantages to establish a nationwide production base [2] Group 2: Product Portfolio - Chengji Pharmaceutical's main products are categorized into three types: clinical injections, solid preparations, and medical devices [3] - Key products include the injection of Acyclovir, exclusive pediatric acetaminophen tablets, and the patented "Hanneng" automatic injection pen [3] - "Hanneng" meets the safety and efficiency needs of healthcare professionals, while "Hanquan" is a state-of-the-art automatic injection technology with significant market potential [3] Group 3: Internationalization and Future Plans - The company is actively expanding its international presence, seeking collaborations for its mature peptide products and progressing with the registration of generic drugs abroad [3] - Hanyu is focusing on maintaining its existing raw material market while exploring international pathways for its formulation products [4] - The company is preparing for a surge in demand for raw materials following the expiration of patents in August 2017, which is expected to boost sales significantly [3]